Profile data is unavailable for this security.
About the company
Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing transformative therapies for rare and neurological diseases with limited treatment options. The Company’s Trappsol Cyclo is a proprietary formulation of hydroxypropyl beta cyclodextrin. It is an orphan drug designated product in the United States and Europe, and is the subject of four formal clinical trials for Niemann-Pick Disease Type C (NPC) disease. NPC is a rare and fatal autosomal recessive genetic disease resulting in disrupted cholesterol metabolism that impacts the brain, lungs, liver, spleen, and other organs. The Company is also engaged in conducting a Phase 2b clinical trial using Trappsol Cyclo intravenously in early Alzheimer’s disease (NCT05607615) based on encouraging data from an Expanded Access program for Alzheimer’s disease (NCT03624842).
- Revenue in USD (TTM)1.08m
- Net income in USD-20.06m
- Incorporated2020
- Employees8.00
- LocationCyclo Therapeutics Inc6714 Nw 16Th Street,, Suite BGAINESVILLE 32653United StatesUSA
- Phone+1 (386) 418-8060
- Websitehttps://www.cyclotherapeutics.com/
More ▼
Mergers & acquisitions
| Acquired company | CYTH:NAQ since announced | Transaction value |
|---|---|---|
| Applied Molecular Transport Inc | -4.38% | 11.94m |
Data delayed at least 15 minutes, as of May 06 2024 21:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Quince Therapeutics Inc | 0.00 | -31.39m | 41.49m | 32.00 | -- | 0.4849 | -- | -- | -0.8424 | -0.8424 | 0.00 | 1.98 | 0.00 | -- | -- | 0.00 | -23.09 | -42.72 | -24.22 | -46.06 | -- | -- | -- | -- | -- | -- | 0.1363 | -- | -- | -- | 39.25 | -- | -5.47 | -- |
| Carmell Corp | 0.00 | -16.88m | 41.88m | 9.00 | -- | 1.88 | -- | -- | -1.53 | -1.46 | 0.00 | 1.07 | -- | -- | -- | 0.00 | -- | -- | -- | -- | 58.60 | -- | -- | -- | -- | -194.46 | 0.0495 | -- | -- | -- | -75.70 | -- | -- | -- |
| Bolt Biotherapeutics Inc | 7.88m | -69.20m | 41.94m | 100.00 | -- | 0.3719 | -- | 5.33 | -1.83 | -1.83 | 0.2083 | 2.96 | 0.0406 | -- | -- | 78,760.00 | -35.71 | -48.32 | -40.23 | -54.03 | -- | -- | -878.58 | -2,267.00 | -- | -- | 0.00 | -- | 37.48 | -- | 21.45 | -- | -6.61 | -- |
| Matinas BioPharma Holdings Inc | 1.10m | -22.94m | 42.14m | 32.00 | -- | 1.90 | -- | 38.45 | -0.1056 | -0.1056 | 0.005 | 0.0886 | 0.0314 | -- | -- | 34,250.00 | -65.62 | -44.62 | -72.81 | -48.25 | -- | -- | -2,093.25 | -2,344.60 | -- | -- | 0.0012 | -- | -65.62 | 55.71 | -9.26 | -- | -16.46 | -- |
| SensaSure Technologies Inc | 1.15k | -1.94m | 42.26m | 1.00 | -- | -- | -- | 36,749.47 | -0.0344 | -0.0344 | 0.00002 | -0.011 | 0.0336 | -- | -- | 1,150.00 | -5,689.09 | -- | -- | -- | -- | -- | -169,534.80 | -- | -- | -2.71 | -- | -- | -31.15 | -- | 17.62 | -- | -- | -- |
| Benson Hill Inc | 473.34m | -111.25m | 42.38m | 270.00 | -- | 0.4842 | -- | 0.0895 | -0.5914 | -0.6131 | 2.52 | 0.4129 | 1.22 | 10.27 | 14.81 | 1,753,096.00 | -28.68 | -- | -38.28 | -- | 4.99 | 3.18 | -23.50 | -40.73 | 0.9166 | -2.33 | 0.4509 | -- | 24.16 | 156.43 | -11.58 | -- | 63.78 | -- |
| Dyadic International Inc | 2.90m | -6.80m | 42.69m | 7.00 | -- | 7.16 | -- | 14.73 | -0.2359 | -0.2359 | 0.1007 | 0.204 | 0.2643 | -- | 7.28 | 414,115.70 | -61.97 | -36.82 | -78.87 | -39.85 | 31.84 | 22.47 | -234.42 | -410.16 | -- | -- | 0.00 | -- | -1.07 | 17.48 | 30.20 | -- | -- | -- |
| Cara Therapeutics Inc | 20.97m | -118.51m | 43.19m | 55.00 | -- | 0.754 | -- | 2.06 | -2.19 | -2.19 | 0.3872 | 1.05 | 0.1361 | 2.37 | 6.96 | 381,236.40 | -76.94 | -35.76 | -91.50 | -40.82 | 70.56 | -- | -565.21 | -162.10 | 4.43 | -- | 0.00 | -- | -49.92 | 9.26 | -38.65 | -- | 100.66 | -- |
| Cyclo Therapeutics Inc | 1.08m | -20.06m | 43.94m | 8.00 | -- | 9.18 | -- | 40.82 | -1.33 | -1.33 | 0.0679 | 0.1666 | 0.1233 | 0.387 | 12.14 | 134,551.30 | -229.72 | -132.22 | -727.50 | -215.17 | 90.85 | 90.37 | -1,863.35 | -1,114.04 | 1.42 | -2,769.34 | 0.00 | -- | -21.76 | 1.25 | -29.81 | -- | -3.95 | -- |
| IN8BIO, Inc. | 0.00 | -30.01m | 43.94m | 31.00 | -- | 1.73 | -- | -- | -1.02 | -1.02 | 0.00 | 0.5761 | 0.00 | -- | -- | 0.00 | -89.91 | -74.18 | -108.07 | -84.42 | -- | -- | -- | -- | -- | -- | 0.0466 | -- | -- | -- | -5.21 | -- | -4.54 | -- |
| Lexaria Bioscience Corp | 404.72k | -5.44m | 43.94m | 5.00 | -- | 6.48 | -- | 108.57 | -0.6851 | -0.6851 | 0.0493 | 0.5264 | 0.0722 | -- | 1.64 | 80,944.00 | -97.62 | -95.67 | -94.18 | -96.58 | 95.66 | 76.98 | -1,351.64 | -1,612.76 | -- | -175.33 | 0.00 | -- | -11.43 | -12.19 | 8.31 | -- | -- | -- |
| Eyenovia Inc | 3.79k | -27.26m | 44.56m | 57.00 | -- | 4.43 | -- | 11,756.61 | -0.6639 | -0.6639 | 0.00009 | 0.1976 | 0.0001 | -- | 0.0031 | 66.49 | -91.15 | -80.31 | -119.11 | -117.70 | 0.00 | -- | -719,290.30 | -680.95 | 2.16 | -15.14 | 0.6135 | -- | -- | -- | 2.68 | -- | 152.20 | -- |
| Movano Inc | 0.00 | -29.28m | 44.73m | 30.00 | -- | 7.37 | -- | -- | -0.6463 | -0.6463 | 0.00 | 0.0618 | 0.00 | -- | -- | 0.00 | -258.41 | -151.50 | -496.87 | -188.58 | -- | -- | -- | -- | 1.26 | -- | 0.014 | -- | -- | -- | 3.45 | -- | 4.24 | -- |
| Xilio Therapeutics Inc | 0.00 | -76.40m | 46.14m | 73.00 | -- | 0.9371 | -- | -- | -2.78 | -2.78 | 0.00 | 1.33 | 0.00 | -- | -- | 0.00 | -76.37 | -- | -93.74 | -- | -- | -- | -- | -- | -- | -131.89 | 0.0826 | -- | -- | -- | 13.40 | -- | -- | -- |
| Sensei Biotherapeutics Inc | 0.00 | -34.10m | 46.15m | 27.00 | -- | 0.7097 | -- | -- | -1.21 | -1.21 | 0.00 | 2.59 | 0.00 | -- | -- | 0.00 | -35.38 | -47.03 | -38.31 | -54.33 | -- | -- | -- | -- | -- | -- | 0.0247 | -- | -- | -- | 29.82 | -- | 42.16 | -- |
| NextCure Inc | 0.00 | -63.73m | 46.16m | 82.00 | -- | 0.4648 | -- | -- | -2.29 | -2.29 | 0.00 | 3.55 | 0.00 | -- | -- | 0.00 | -45.05 | -22.59 | -47.72 | -23.54 | -- | -- | -- | -964.96 | -- | -- | 0.00 | -- | -- | -- | 16.07 | -- | -23.17 | -- |
Data as of May 06 2024. Currency figures normalised to Cyclo Therapeutics Inc's reporting currency: US Dollar USD
2.45%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2023 | 355.22k | 1.24% |
| Geode Capital Management LLCas of 31 Dec 2023 | 152.08k | 0.53% |
| Citadel Securities LLCas of 31 Dec 2023 | 54.02k | 0.19% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 39.76k | 0.14% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 39.53k | 0.14% |
| Wealth Enhancement Advisory Services LLCas of 31 Mar 2024 | 20.40k | 0.07% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2023 | 17.45k | 0.06% |
| XTX Markets LLCas of 31 Dec 2023 | 10.70k | 0.04% |
| BlackRock Advisors LLCas of 31 Dec 2023 | 8.69k | 0.03% |
| Tower Research Capital LLCas of 31 Dec 2023 | 5.87k | 0.02% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
